TL;DR
This study models the cost-effectiveness of implementing pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) and transgender women (TGW) in Brazil. The findings strongly support PrEP as a highly cost-effective intervention that significantly increases life expectancy and reduces HIV infection risk in this vulnerable population.
What Problem Does This Paper Address?
The paper addresses the significant burden of HIV infection among men who have sex with men (MSM) and transgender women (TGW) in Brazil. These populations experience disproportionately high rates of HIV incidence and prevalence compared to the general population. While pre-exposure prophylaxis (PrEP) has shown promise globally in preventing HIV infection, its cost-effectiveness within the Brazilian healthcare system, considering its specific epidemiological context and economic constraints, was not well-established. The study aims to fill this gap by evaluating the clinical and economic outcomes of implementing a daily tenofovir/emtricitabine (TDF/FTC) PrEP program for these high-risk groups in Brazil.
Methods
The researchers utilized the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-International model, a well-established simulation model for HIV prevention and treatment. This Monte Carlo simulation tracks individuals from model entry until death, accounting for HIV infection, detection, disease progression, and treatment.
Two strategies were compared:
- No PrEP (Standard of Care): This strategy represents the current standard of care in Brazil, which includes universal access to antiretroviral therapy (ART).
- PrEP Strategy: This strategy includes the standard of care plus daily TDF/FTC PrEP until age 50.
Key outcomes measured included lifetime HIV infection risk, life expectancy (LE), lifetime HIV-related medical costs, and the incremental cost-effectiveness ratio (ICER) expressed in 2015 US dollars per year of life saved (YLS). The analysis was conducted from the perspective of the Brazilian National Health System, with a willingness-to-pay threshold based on Brazil's annual per capita GDP. Sensitivity analyses were performed to assess the robustness of the findings to variations in key parameters.
Datasets
The study used data from various sources to parameterize the CEPAC-International model, including:
- PrEP Brasil: A local demonstration project in Brazil that provided data on PrEP uptake, adherence, and associated costs.
- Brazilian Ministry of Health: Provided data on HIV prevalence, incidence, ART guidelines, and drug costs.
- Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz): Provided data on HIV-infected cohort characteristics, opportunistic infection risks, and mortality.
- Published literature: Cited for epidemiological data, PrEP efficacy estimates, and cost information.
No new datasets were introduced; rather, existing Brazilian and international data were integrated into the established modeling framework.
Key Insights and Ideas
- PrEP is a powerful tool for life extension: The most striking insight is the substantial increase in life expectancy for individuals using PrEP, even after accounting for discounting. This highlights PrEP's direct impact on longevity.
- Significant reduction in HIV risk: PrEP dramatically lowers both short-term (five-year) and lifetime HIV infection risks for MSM and TGW.
- Cost-effectiveness is robust: The study found that PrEP remains cost-effective even when key parameters like PrEP effectiveness, drug costs, and HIV incidence are varied within plausible ranges. This suggests a strong economic justification for its implementation.
- PrEP's dual role: Beyond prevention, PrEP also facilitates earlier detection and linkage to care for breakthrough infections, contributing to better health outcomes and influencing the overall cost profile of HIV management.
- Brazilian context is crucial: The analysis is tailored to Brazil's specific economic and epidemiological landscape, using local GDP as a benchmark for cost-effectiveness, making the findings directly relevant to policymakers in the country.
Key Results
- Life Expectancy: PrEP increased undiscounted life expectancy by 4.2 years (from 36.8 to 41.0 years) and discounted life expectancy by 1.7 years (from 20.7 to 22.4 years).
- HIV Infection Risk: Lifetime HIV infection risk decreased from 50.5% with no PrEP to 40.1% with PrEP.
- Costs: Lifetime discounted HIV-related medical costs increased from $4100 per person with no PrEP to $8420 with PrEP.
- Incremental Cost-Effectiveness Ratio (ICER): The ICER for PrEP compared to no PrEP was $2530 per YLS, which is approximately 30% of Brazil's 2015 GDP per capita ($8540). This falls well below the commonly accepted threshold for cost-effectiveness.
- Cost-Effectiveness Threshold: PrEP remained cost-effective until PrEP drug costs exceeded $100 per month.
Limitations and Future Work
The authors acknowledge several limitations:
- Data Scarcity for TGW: The study combined MSM and TGW into a single population due to limited specific data for TGW in Brazil. Future work should refine analyses with TGW-specific data.
- Quality of Life: The cost-effectiveness measure used (YLS) does not account for the quality of life, which is a more comprehensive measure. Future studies could incorporate quality-adjusted life years (QALYs) if appropriate Brazilian valuation data become available.
- Budget Impact: While cost-effectiveness is established, the study did not fully explore the budget impact of large-scale PrEP implementation, which is a critical next step for policymakers.
- Generic Manufacturing and ART Advancements: The potential for generic TDF/FTC manufacturing and the introduction of newer ART regimens could influence future cost-effectiveness calculations.
- Stigma and Discrimination: The study acknowledges that stigma and discrimination can be barriers to care and PrEP uptake, which were not fully quantified in the model.
- "Seasons of Risk": The analysis did not explore the potential cost-savings of limiting PrEP use to periods of highest risk or susceptibility.
Future work should focus on budget impact analyses, incorporating TGW-specific data, and exploring the impact of episodic PrEP use. Continued monitoring of HIV incidence in Brazil is also crucial.
Summary updated